Global Allogeneic Cell Therapy Market to 2030: Increasing FDA Approvals of Allogeneic Cell Therapies Drives Growth
May 31, 2023 08:43 ET
|
Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Allogeneic Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Stem Cell, Non-stem Cell), By Therapeutic Area (Hematological...
Global Genome Editing/Genome Engineering Market Report 2023: Rising Prevalence of Cancer and Other Genetic Disorders Fuels the Sector
May 30, 2023 07:58 ET
|
Research and Markets
Dublin, May 30, 2023 (GLOBE NEWSWIRE) -- The "Genome Editing/Genome Engineering Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Global Gene Editing Technologies Market Report 2023: Sector is Expected to Reach $16.37 Billion by 2032 at a CAGR of 27.5%
May 30, 2023 06:08 ET
|
Research and Markets
Dublin, May 30, 2023 (GLOBE NEWSWIRE) -- The "Gene Editing Technologies Market - A Global and Regional Analysis: Focus on Offering, Technology, Application, End User, and Region - Analysis and...
Gene Editing Global Market Report 2023: Rising Infectious Diseases Fuel the Sector
May 12, 2023 10:03 ET
|
Research and Markets
Dublin, May 12, 2023 (GLOBE NEWSWIRE) -- The "Gene Editing Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and...
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 04, 2023 07:30 ET
|
Intellia Therapeutics, Inc.
Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to submit...
Macomics Presents its ENIGMAC™ Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR
April 17, 2023 13:30 ET
|
Macomics Limited
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery has presented data demonstrating the power of its...
United Kingdom Cell & Gene Therapy Business and Investment Opportunities Databook - Q1 2023 Update
April 14, 2023 07:33 ET
|
Research and Markets
Dublin, April 14, 2023 (GLOBE NEWSWIRE) -- The "United Kingdom Cell & Gene Therapy Business and Investment Opportunities Databook - Q1 2023 Update" report has been added to ...
Transfection Reagents and Equipment Global Market Report 2023: Growing Demand for Synthetic Genes Fuels Sector
March 21, 2023 06:53 ET
|
Research and Markets
Dublin, March 21, 2023 (GLOBE NEWSWIRE) -- The "Transfection Reagents and Equipment Market by Product, by Method, by Application, by End User, and by Region - Global Forecast to 2022-2033" report...
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
March 02, 2023 07:00 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Global Cell & Gene Therapy Business and Investment Opportunities Q1 2023 Update: Mergers and Acquisitions Continue to Dominate Growth Prospects
February 24, 2023 08:53 ET
|
Research and Markets
Dublin, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The "Global Cell & Gene Therapy Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial...